Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies

      

Fri, 07 Apr 2006, 15:40:00 EDT

SAN MARINO, CA - Apr. 7 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila.

SAN MARINO, CA - April 7 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila.

In a statement to the press, Dr. Erlinda Maria Gordon, M.D., Chairman, added: "We are pleased that the value of Rexin-G(TM) in the management of cancer is being appreciated by the international medical community, and that patients who are refractory to conventional chemotherapy now have additional options."

Ideally suited, by design, to function within the context of the human circulatory system, Rexin-G(TM) represents the first in a series of truly effective targeted genetic medicines that seek out and destroy metastatic cancer, without eliciting deleterious side effects or organ damage.

The unique Targeted Delivery System (TDS technology) engineered into Rexin-G(TM) carries a tumor-killing designer gene selectively to diseased tissues with such precision that a new term - "Pathotropic (or disease-seeking) Medicine" - was required to describe its properties. Rexin-G(TM) recently gained FDA Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials at several American institutions, including Mayo Clinic in Minnesota.

Website: http://www.epeiusbiotech.com

NEWS SOURCE: Epeius Biotechnologies Corporation

NOTICE: THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Epeius Biotechnologies Corporation), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS OR CONCERNS ABOUT THIS NEWS ANNOUNCEMENT, PLEASE CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE (SEND2PRESS).
Send2Press® is the originating wire service for this story “Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies” and content is Copr. © 2006 Epeius Biotechnologies Corporation with newswire copy Copr. © 2006 Send2Press (a service of Neotrope). All trademarks acknowledged.

TERMS OF USE: rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
Reads as of Tuesday, Oct 21 2014 - 21:32:25 PM EDT:
7159 times (1 today, 4 this week, 21 this month, 292 this year)